首页> 外文OA文献 >Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

【2h】

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

机译：用贝伐珠单抗化疗的转移性结直肠癌（mCRC）患者中CD133的药物遗传学谱与反应率（RR）和无进展生存期（PFS）相关

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Pohl, A; El-Khoueiry, A; Yang, D; Zhang, W; Lurje, G; Ning, Y; Winder, T; Hu-Lieskoven, S; Iqbal, S; Danenberg, K D; Kahn, M; Teo, J L; Shriki, J; Stebbing, J; Lenz, H J;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy [J] . PohlA., El-KhoueiryA., YangD., The pharmacogenomics journal . 2013 ,第2期

机译：用贝伐珠单抗化疗的转移性结直肠癌（mCRC）患者中CD133的药物遗传学谱与反应率（RR）和无进展生存期（PFS）相关
2. CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy [J] . Matsusaka S., Cao S., Hanna D. L., The pharmacogenomics journal . 2017 ,第6期

机译：CXCR4多态性预测，通过一线贝伐单抗化疗治疗的转移性结直肠癌患者的无进展生存
3. Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response-a retrospective study [J] . Yang Yuan-Hao, Lin Jen-Kou, Chen Wei-Shone, Journal of Cancer Research and Clinical Oncology . 2014 ,第11期

机译：西妥昔单抗与贝伐单抗作为转移性结直肠癌患者一线生物化学疗法的比较：回顾性研究显示，无进展生存率仅限于可测量肿瘤和客观肿瘤反应的患者
4. Single Cell Genomic Profiling of Circulating Tumor Cells (CTCs) from Metastatic Colorectal Cancer (mCRC) Identify Tumor Heterogeneity and Rare Somatic Driver Alterations [C] . Stephanie Greene, Angel Rodriguez, Jerry Lee, International Molecular Medicine Tri-Conference. . 2016

机译：转移结直肠癌（MCRC）的循环肿瘤细胞（CTC）的单细胞基因组分析识别肿瘤异质性和稀有躯体驾驶员改变
5. Impact of Erythropoiesis Stimulating Agents on Survival and Risk of Venous Thromboembolism Among Patients with Colorectal Cancer Receiving Chemotherapy. [D] . Sato, Masayo. 2012

机译：红细胞生成刺激剂对接受化疗的结直肠癌患者生存率和静脉血栓栓塞风险的影响。
6. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression–free survival (PFS) in patients with metastatic colorectal cancer (mCRC) treated with bevacizumab-based chemotherapy [O] . Alexandra Pohl, Anthony El-Khoueiry, Dongyun Yang, -1

机译：CD133的药物发生谱与转移性结直肠癌（MCRC）患者的反应率（RR）和无进展的存活（PFS）有关用贝伐单抗基化疗治疗
7. Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months. [O] . Axel Grothey, Alfredo Falcone, Yves Humblet, 2015

机译：亚群分析患者患有术治疗（PFS）的Regorafenib（reg）治疗的转移性结直肠癌（incar）治疗的患者（ing），患者患者超过4个月。

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

著录项

相似文献

相关主题

期刊订阅